Stock data
Rhythm Pharmaceuticals, Inc. (RYTM)
Rhythm Pharmaceuticals, Inc. (RYTM) reported revenue of US$189.76M and net income of -US$196.54M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$189.76M | — | -US$192.02M | -US$196.54M | — |
| 2024 | US$130.13M | — | -US$265.50M | -US$260.60M | — |
| 2023 | US$77.43M | — | -US$184.36M | -US$184.68M | — |
| 2022 | US$23.64M | — | -US$179.16M | -US$181.12M | — |
| 2021 | US$3.15M | — | -US$170.06M | -US$69.61M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$71.25M | -US$49.30M | — |
| 2026-03-31 | US$60.11M | -US$55.64M | — |
| 2025-12-31 | US$57.25M | -US$47.51M | — |
| 2025-09-30 | US$51.30M | -US$52.90M | — |
| 2025-06-30 | US$48.50M | -US$46.63M | — |
| 2025-03-31 | US$32.70M | -US$49.50M | — |
| 2024-12-31 | US$41.83M | -US$43.33M | — |
| 2024-09-30 | US$33.25M | -US$43.64M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.